Why is the CSL (ASX:CSL) share price struggling in December?

What's happened to CSL lately?

| More on:
A man sits in front of his laptop computer with his head on his hand and a sad, dejected look on his face after seeing how far Whitehaven shares have fallen today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has dived about 12% since the start of December. On Friday, the global biotech's shares finished the session down 0.33% to $272.10 apiece.

What's weighing down CSL shares?

A few factors have had a negative impact on the CSL share price, prompting investors to hit the sell button.

Firstly, the rapid spread of the COVID-19 omicron variant has spooked the market since its discovery on 24 November. The S&P/ASX 200 Index (ASX: XJO) sunk to a low of 7,168 points on 2 December, before slightly recovering. On Friday, the benchmark index finished trading at 7,304 points, up 0.1% for the day.

One of the main challenges CSL has faced during the pandemic is a reduction in its plasma collections due to lockdowns. Australia is currently facing a surge in COVID-19 cases, particularly in New South Wales and Victoria.

In addition, the company announced an institutional placement this week to raise $6.3 billion to purchase Vifor Pharma. To put this in perspective, this is Australia's second largest equity raise, behind Telstra Corporation Ltd (ASX: TLS). It's also the world's seventh-largest equity raise for 2021.

The placement price of $273.00 per share would see about 23.1 million new CSL shares brought onto the company's registry. CSL also revealed it would launch a $750 million share purchase plan, offering the same terms to retail investors.

When CSL shares came out of a trading halt on Thursday, investors dumped them and the share price fell by 8.16%. This was the company's biggest one-day decline since the beginning of the pandemic in March 2020.

With more shares being added to the company's books, this will inevitably dilute shareholder value. 

The CSL share price could be an attractive buy for the medium-term. Analysts at Morgans raised their price target by 3.2% to $334.70 on Thursday. Based on CSL's last closing price, this represents an upside of 23%.

CSL share price summary

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, down 5.5%. Over the year, the shares have traded between $242 and $319.78.

On valuation grounds, CSL is the second largest company on the ASX with a market capitalisation of roughly $124.44 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »